Drug Profile
MCT 465
Alternative Names: MCT-465Latest Information Update: 28 Sep 2018
Price :
$50
*
At a glance
- Originator MultiCell Technologies Inc
- Developer MultiCell Technologies Inc; University Health Network
- Class Antivirals; RNA
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Immunostimulants; T lymphocyte stimulants; Toll-like receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Liver cancer; Viral hepatitis
- Discontinued Influenza virus infections
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for preclinical development in Viral-hepatitis in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Liver-cancer in USA (Parenteral)